BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22931646)

  • 21. S-adenosylmethionine regulates thiopurine methyltransferase activity and decreases 6-mercaptopurine cytotoxicity in MOLT lymphoblasts.
    Milek M; Karas Kuzelicki N; Smid A; Mlinaric-Rascan I
    Biochem Pharmacol; 2009 Jun; 77(12):1845-53. PubMed ID: 19428339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Classification and regression tree-based prediction of 6-mercaptopurine-induced leucopenia grades in children with acute lymphoblastic leukemia.
    Naushad SM; Dorababu P; Rupasree Y; Pavani A; Raghunadharao D; Hussain T; Alrokayan SA; Kutala VK
    Cancer Chemother Pharmacol; 2019 May; 83(5):875-880. PubMed ID: 30806759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of Thiopurine S-Methyltransferase Deficient Alleles in Acute Lymphoblastic Leukemia Patients in Mexican Patients.
    Jiménez-Morales S; Ramírez-Florencio M; Mejía-Aranguré JM; Núñez-Enríquez JC; Bekker-Mendez C; Torres-Escalante JL; Flores-Lujano J; Jiménez-Hernández E; Del Carmen Rodríguez-Zepeda M; Leal YA; González-Montalvo PM; Pantoja-Guillen F; Peñaloza-Gonzalez JG; Gutiérrez-Juárez EI; Núñez-Villegas NN; Pérez-Saldivar ML; Guerra-Castillo FX; Flores-Villegas LV; Ramos-Cervantes MT; Fragoso JM; García-Escalante MG; Del Carmen Pinto-Escalante D; Ramírez-Bello J; Hidalgo-Miranda A
    Arch Med Res; 2016 Nov; 47(8):615-622. PubMed ID: 28476189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of TPMT, ITPA, and NUDT15 Variants during Mercaptopurine Treatment of Swedish Pediatric Patients with Acute Lymphoblastic Leukemia.
    Wahlund M; Nilsson A; Kahlin AZ; Broliden K; Myrberg IH; Appell ML; Berggren A
    J Pediatr; 2020 Jan; 216():150-157.e1. PubMed ID: 31635813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia.
    Lennard L; Richards S; Cartwright CS; Mitchell C; Lilleyman JS; Vora A;
    Clin Pharmacol Ther; 2006 Oct; 80(4):375-83. PubMed ID: 17015055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status.
    Stocco G; Crews KR; Evans WE
    Expert Opin Drug Saf; 2010 Jan; 9(1):23-37. PubMed ID: 20021291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond.
    Karas-Kuzelicki N; Mlinaric-Rascan I
    Pharmacogenomics; 2009 Aug; 10(8):1309-22. PubMed ID: 19663675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The low frequency of defective TPMT alleles in Turkish population: a study on pediatric patients with acute lymphoblastic leukemia.
    Tumer TB; Ulusoy G; Adali O; Sahin G; Gozdasoglu S; Arinç E
    Am J Hematol; 2007 Oct; 82(10):906-10. PubMed ID: 17617792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia?
    Fakhoury M; Andreu-Gallien J; Mahr A; Medard Y; Azougagh S; Vilmer E; Jacqz-Aigrain E
    J Clin Pharm Ther; 2007 Dec; 32(6):633-9. PubMed ID: 18021342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of thiopurine methyltransferase gene polymorphism on Egyptian children with acute lymphoblastic leukaemia.
    Tantawy AAG; Ebeid FSE; Adly AAM; El-Ghoroury E; Mostafa M
    J Genet; 2017 Dec; 96(6):905-910. PubMed ID: 29321348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No association between relapse hazard and thiopurine methyltransferase geno- or phenotypes in non-high risk acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
    Nielsen SN; Toksvang LN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Appell ML; Hjalgrim LL; Schmiegelow K
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):271-279. PubMed ID: 33928426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association Between Combined Presence of Hepatitis C Virus and Polymorphisms in Different Genes With Toxicities of Methotrexate and 6-Mercaptopurine in Children With Acute Lymphoblastic Leukemia.
    Abdelaziz DH; Elhosseiny NM; Khaleel SA; Sabry NA; Attia AS; El-Sayed MH
    Pediatr Blood Cancer; 2016 Sep; 63(9):1539-45. PubMed ID: 27163515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TPMT gene expression is increased during maintenance therapy in childhood acute lymphoblastic leukemia patients in a TPMT gene promoter variable number of tandem repeat-dependent manner.
    Kotur N; Dokmanovic L; Janic D; Stankovic B; Krstovski N; Tosic N; Katsila T; Patrinos GP; Zukic B; Pavlovic S
    Pharmacogenomics; 2015; 16(15):1701-12. PubMed ID: 26411491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methotrexate binds to recombinant thiopurine S-methyltransferase and inhibits enzyme activity after high-dose infusions in childhood leukaemia.
    Wennerstrand P; Mårtensson LG; Söderhäll S; Zimdahl A; Appell ML
    Eur J Clin Pharmacol; 2013 Sep; 69(9):1641-9. PubMed ID: 23660772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of
    Nghia H; Than HH; Dong CV; Oanh TTK; Truc VTT; Ngan CTT; Ngon HT; Binh NT; Dung PC; Anh Vu H; Xinh PT
    Pediatr Hematol Oncol; 2022 Sep; 39(6):561-570. PubMed ID: 35156873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic variants of thiopurine and folate metabolic pathways determine 6-MP-mediated hematological toxicity in childhood ALL.
    Dorababu P; Naushad SM; Linga VG; Gundeti S; Nagesh N; Kutala VK; Reddanna P; Digumarti R
    Pharmacogenomics; 2012 Jul; 13(9):1001-8. PubMed ID: 22838948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6-mercaptopurine dosing in children with acute lymphoblastic leukemia.
    Donnan JR; Ungar WJ; Mathews M; Hancock-Howard RL; Rahman P
    Pediatr Blood Cancer; 2011 Aug; 57(2):231-9. PubMed ID: 21344614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics.
    Lennard L; Cartwright CS; Wade R; Vora A
    Br J Haematol; 2015 Apr; 169(2):228-40. PubMed ID: 25441457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dosage of 6-Mercaptopurine in Relation to Genetic TPMT and ITPA Variants: Toward Individualized Pediatric Acute Lymphoblastic Leukemia Maintenance Treatment.
    Kouwenberg TW; van den Bosch BJC; Bierau J; Te Loo DMWM; Coenen MJH; Hagleitner MM
    J Pediatr Hematol Oncol; 2020 Mar; 42(2):e94-e97. PubMed ID: 31895215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Significance of NUDT15 gene in individualized treatment with 6-mercaptopurine in children with acute lymphoblastic leukemia].
    He J; Liu L
    Zhongguo Dang Dai Er Ke Za Zhi; 2019 Jan; 21(1):100-104. PubMed ID: 30675872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.